BDX Becton Dickinson
NYSE · SEC CIK 10795 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $2.78M 21 sales by 5 insiders
- Filings on record
- 294 since 2021-08-04, latest 2026-09-03 19:24
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Polen Thomas E Jr | COB, CEO, Pres, Dir | — | $1.17M |
| Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | — | $784.2K |
| Goette Roland | EVP, Pres, EMEA | — | $440.9K |
| SCOTT BERTRAM L | Dir | — | $212.3K |
| Feld Michael | EVP, Pres, Life Sciences | — | $167.4K |
| Menziuso Peter | EVP, Pres, BDI | — | — |
| Roque Vitor | Interim CFO | — | — |
| Spikner Pamela L. | SVPController, Chief Acct Off | — | — |
| Shan David | EVP, Chief ISC Off | — | — |
| Waldstreicher Joanne | Dir | — | — |
Transactions 334
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 19:24 | 2026-09-02 | BDX | Roque Vitor | EVP, CFO | F - Tax | $0.00 | -190 | 8,041 | -2% | $0 | |
| T | 2026-08-27 16:28 | 2026-08-26 | BDX | Feld Michael | EVP, Chief Revenue Off | S - Sale | $188.49 | -165 | 19.7K | -0.8% | -$31.1K |
| 2026-08-24 16:19 | 2026-08-20 | BDX | Feld Michael | EVP, Chief Revenue Off | F - Tax | $0.00 | -1,049 | 19.9K | -5% | $0 | |
| DT | 2026-08-14 16:36 | 2026-08-13 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | M - OptEx | $167.25 | +43.3K | 153.4K | +39% | +$7.24M |
| DT | 2026-08-14 16:36 | 2026-08-13 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | D - Sale to Iss | $185.00 | -39.1K | 114.3K | -25% | -$7.24M |
| DT | 2026-08-14 16:36 | 2026-08-13 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | S - Sale+OE | $185.00 | -4,152 | 110.2K | -4% | -$768.1K |
| 2026-08-12 17:27 | 2026-08-11 | BDX | Goette Roland | EVP, Pres, EMEA | S - Sale | $180.84 | -2,438 | 14.9K | -14% | -$440.9K | |
| T | 2026-07-28 11:16 | 2026-07-27 | BDX | Feld Michael | EVP, Chief Revenue Off | S - Sale | $157.13 | -75 | 20.9K | -0.4% | -$11.8K |
| 2026-07-06 15:16 | 2026-07-01 | BDX | Muhsin Bilal | EVP, Pres Connected Care | A - Grant | $0.00 | +14.3K | 43.3K | +50% | $0 | |
| 2026-07-06 15:16 | 2026-07-02 | BDX | Muhsin Bilal | EVP, Pres Connected Care | F - Tax | $0.00 | -1,935 | 41.4K | -4% | $0 | |
| T | 2026-06-26 20:47 | 2026-06-26 | BDX | Feld Michael | EVP, Chief Revenue Off | S - Sale | $152.80 | -75 | 21.0K | -0.4% | -$11.5K |
| T | 2026-06-25 10:16 | 2026-06-24 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | S - Sale | $145.66 | -1,100 | 13.2K | -8% | -$160.2K |
| T | 2026-06-11 17:21 | 2026-06-10 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | S - Sale | $151.48 | -1,100 | 14.3K | -7% | -$166.6K |
| DT | 2026-06-03 12:44 | 2026-06-01 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | M - OptEx | $126.16 | +20.2K | 125.7K | +19% | +$2.55M |
| DT | 2026-06-03 12:44 | 2026-06-01 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | D - Sale to Iss | $146.15 | -17.4K | 108.2K | -14% | -$2.55M |
| DT | 2026-06-03 12:44 | 2026-06-01 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | S - Sale+OE | $146.35 | -2,764 | 110.2K | -2% | -$404.5K |
| 2026-06-02 14:11 | 2026-06-01 | BDX | Menziuso Peter | EVP, Pres, BDI | A - Grant | $0.00 | +14.3K | 14.3K | New | $0 | |
| T | 2026-05-27 13:41 | 2026-05-26 | BDX | Feld Michael | EVP, Chief Revenue Off | S - Sale | $147.35 | -75 | 21.1K | -0.4% | -$11.1K |
| 2026-05-08 17:04 | 2026-05-07 | BDX | Roque Vitor | EVP, CFO | A - Grant | $0.00 | +1,721 | 8,231 | +26% | $0 | |
| T | 2026-04-28 07:44 | 2026-04-27 | BDX | Feld Michael | EVP, Chief Revenue Off | S - Sale | $151.94 | -74 | 21.2K | -0.3% | -$11.2K |
| 2026-04-06 17:28 | 2026-04-06 | BDX | Neal Shana Carol | EVP, CHRO | F - Tax | $0.00 | -1,146 | 24.0K | -5% | $0 | |
| 2026-03-27 | 2026-03-26 | BDX | Feld Michael | EVP, Chief Revenue Off | S - Sale | $156.83 | -75 | 21.2K | -0.4% | -$11.8K | |
| 2026-03-17 | 2026-03-16 | BDX | Minnix Lanesha | EVP, GC | A - Grant | $0.00 | +7,492 | 7,492 | New | $0 | |
| 2026-03-04 | 2026-03-02 | BDX | Roque Vitor | Interim CFO | A - Grant | $0.00 | +931 | 6,510 | +17% | $0 | |
| 2026-03-04 | 2026-03-02 | BDX | Spikner Pamela L. | CAO, SVP Ctrl | A - Grant | $0.00 | +931 | 3,323 | +39% | $0 | |
| 2026-02-27 | 2026-02-26 | BDX | Feld Michael | EVP, Chief Revenue Off | S - Sale | $181.84 | -75 | 21.3K | -0.4% | -$13.6K | |
| 2026-02-18 | 2026-02-18 | BDX | SCOTT BERTRAM L | Dir | S - Sale | $182.61 | -953 | 36.8K | -3% | -$174.0K | |
| 2026-01-29 | 2026-01-27 | BDX | HAYES GREGORY | Dir | A - Grant | $0.00 | +1,098 | 7,159 | +18% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | Jones Christopher Ian Montague | Dir | A - Grant | $0.00 | +1,098 | 24.3K | +5% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | Henderson Jeffrey William | Dir | A - Grant | $0.00 | +1,098 | 9,143 | +14% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | RING TIMOTHY M | Dir | A - Grant | $0.00 | +1,098 | 59.2K | +2% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | ECKERT R ANDREW | Dir | A - Grant | $0.00 | +1,098 | 10.4K | +12% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | Byington Carrie L | Dir | A - Grant | $0.00 | +1,098 | 5,018 | +28% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | Huffines Robert Luther | Dir | A - Grant | $0.00 | +1,098 | 1,279 | +607% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | Brown William M | Dir | A - Grant | $0.00 | +1,098 | 4,663 | +31% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | Wright Jacqueline | Dir | A - Grant | $0.00 | +1,098 | 1,279 | +607% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | SCOTT BERTRAM L | Dir | A - Grant | $0.00 | +1,098 | 37.7K | +3% | $0 | |
| 2026-01-29 | 2026-01-27 | BDX | Waldstreicher Joanne | Dir | A - Grant | $0.00 | +1,098 | 3,391 | +48% | $0 | |
| 2026-01-28 | 2026-01-26 | BDX | Feld Michael | EVP, CRO, Pres. Life Sciences | S - Sale | $202.73 | -75 | 16.4K | -0.5% | -$15.2K | |
| 2026-01-23 | 2026-01-21 | BDX | Spikner Pamela L. | CAO, SVP Ctrl | F - Tax | $0.00 | -84 | 1,832 | -4% | $0 | |
| DM | 2026-01-16 | 2026-01-15 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | S - Sale+OE | $207.46 | -1,610 | 13.1K | -11% | -$334.0K |
| D | 2026-01-16 | 2026-01-15 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | M - OptEx | $167.91 | +3,054 | 16.2K | +23% | +$512.8K |
| D | 2026-01-16 | 2026-01-15 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | D - Sale to Iss | $209.00 | -2,454 | 13.7K | -15% | -$512.9K |
| 2026-01-06 | 2026-01-03 | BDX | Shan David | EVP, Chief ISC Off | F - Tax | $0.00 | -44 | 8,926 | -0.5% | $0 | |
| 2025-12-29 | 2025-12-26 | BDX | Feld Michael | EVP, CRO, Pres. Life Sciences | S - Sale | $196.08 | -74 | 16.5K | -0.4% | -$14.5K | |
| 2025-12-17 | 2025-12-17 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | S - Sale | $196.03 | -629 | 13.1K | -5% | -$123.3K | |
| 2025-12-02 | 2025-12-01 | BDX | Huffines Robert Luther | Dir | A - Grant | $0.00 | +180 | 180 | New | $0 | |
| 2025-12-02 | 2025-12-01 | BDX | Feld Michael | EVP, CRO, Pres. Life Sciences | S - Sale | $193.36 | -75 | 16.6K | -0.5% | -$14.5K | |
| 2025-12-02 | 2025-12-01 | BDX | Wright Jacqueline | Dir | A - Grant | $0.00 | +180 | 180 | New | $0 | |
| 2025-12-01 | 2025-11-26 | BDX | DelOrefice Christopher | EVP, CFO | F - Tax | $0.00 | -4,245 | 23.0K | -16% | $0 | |
| 2025-12-01 | 2025-11-26 | BDX | DelOrefice Christopher | EVP, CFO | A - Grant | $0.00 | +6,006 | 27.2K | +28% | $0 | |
| 2025-12-01 | 2025-11-26 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | F - Tax | $0.00 | -1,769 | 13.7K | -11% | $0 | |
| M | 2025-12-01 | 2025-11-26 | BDX | Garrison Michael David | EVP, Pres Med.Essntl, BioPharm | A - Grant | $0.00 | +10.6K | 12.5K | +577% | $0 |
| M | 2025-12-01 | 2025-11-26 | BDX | Mocherla Pavan Kumar | EVP, Pres, Greater Asia | A - Grant | $0.00 | +2,916 | 5,055 | +136% | $0 |
| M | 2025-12-01 | 2025-11-26 | BDX | Neal Shana Carol | EVP, CHRO | A - Grant | $0.00 | +10.3K | 20.3K | +102% | $0 |
| 2025-12-01 | 2025-11-26 | BDX | Neal Shana Carol | EVP, CHRO | F - Tax | $0.00 | -2,454 | 21.3K | -10% | $0 | |
| D | 2025-12-01 | 2025-11-26 | BDX | Polen Thomas E Jr | COB, CEO, Pres | A - Grant | $0.00 | +22.5K | 122.9K | +22% | $0 |
| D | 2025-12-01 | 2025-11-26 | BDX | Polen Thomas E Jr | COB, CEO, Pres | F - Tax | $0.00 | -17.4K | 105.5K | -14% | $0 |
| 2025-12-01 | 2025-11-26 | BDX | Feld Michael | EVP, CRO, Pres. Life Sciences | A - Grant | $0.00 | +8,829 | 17.1K | +107% | $0 | |
| 2025-12-01 | 2025-11-26 | BDX | Feld Michael | EVP, CRO, Pres. Life Sciences | F - Tax | $0.00 | -419 | 16.7K | -2% | $0 | |
| M | 2025-12-01 | 2025-11-26 | BDX | Shan David | EVP, Chief ISC Off | A - Grant | $0.00 | +4,529 | 8,079 | +128% | $0 |
| 2025-12-01 | 2025-11-26 | BDX | Shan David | EVP, Chief ISC Off | F - Tax | $0.00 | -134 | 8,970 | -1% | $0 | |
| 2025-12-01 | 2025-11-26 | BDX | Muhsin Bilal | EVP, Pres Connected Care | A - Grant | $0.00 | +9,530 | 21.8K | +78% | $0 | |
| M | 2025-12-01 | 2025-11-26 | BDX | Goette Roland | EVP, Pres, EMEA | A - Grant | $0.00 | +3,143 | 16.1K | +24% | $0 |
| 2025-12-01 | 2025-11-26 | BDX | Goette Roland | EVP, Pres, EMEA | F - Tax | $0.00 | -138 | 17.2K | -0.8% | $0 | |
| 2025-12-01 | 2025-11-26 | BDX | Byrd Richard | EVP, Pres Interventional | F - Tax | $0.00 | -1,719 | 13.8K | -11% | $0 | |
| M | 2025-12-01 | 2025-11-26 | BDX | Byrd Richard | EVP, Pres Interventional | A - Grant | $0.00 | +8,832 | 13.2K | +203% | $0 |
| 2025-12-01 | 2025-11-26 | BDX | Spikner Pamela L. | SVPController, Chief Acct Off | A - Grant | $0.00 | +1,234 | 1,916 | +181% | $0 | |
| 2025-11-07 | 2025-11-07 | BDX | SCOTT BERTRAM L | Dir | S - Sale | $176.58 | -217 | 35.8K | -0.6% | -$38.3K | |
| 2025-10-28 | 2025-10-27 | BDX | Feld Michael | EVP, Pres, Life Sciences | S - Sale | $186.01 | -57 | 8,245 | -0.7% | -$10.6K | |
| 2025-09-29 | 2025-09-26 | BDX | Feld Michael | EVP, Pres, Life Sciences | S - Sale | $181.03 | -58 | 8,302 | -0.7% | -$10.5K | |
| 2025-09-11 | 2025-09-10 | BDX | Fraser Claire | Dir | S - Sale | $187.50 | -917 | 22.2K | -4% | -$171.9K | |
| 2025-09-02 | 2025-09-01 | BDX | Byrd Richard | EVP, Pres Interventional | F - Tax | $0.00 | -216 | 6,736 | -3% | $0 | |
| 2025-09-02 | 2025-09-01 | BDX | DelOrefice Christopher | EVP, CFO | F - Tax | $0.00 | -278 | 21.2K | -1% | $0 | |
| 2025-08-26 | 2025-08-22 | BDX | Feld Michael | EVP, Pres, Life Sciences | S - Sale | $197.99 | -57 | 8,360 | -0.7% | -$11.3K | |
| 2025-08-22 | 2025-08-20 | BDX | Feld Michael | EVP, Pres, Life Sciences | F - Tax | $0.00 | -773 | 8,417 | -8% | $0 | |
| 2025-08-11 | 2025-08-11 | BDX | HAYES GREGORY | Dir | P - Purchase | $191.57 | +5,250 | 6,046 | +660% | +$1.01M | |
| 2025-08-08 | 2025-08-08 | BDX | Fraser Claire | Dir | S - Sale | $192.30 | -863 | 23.1K | -4% | -$166.0K | |
| D | 2025-07-22 | 2025-07-18 | BDX | Garrison Michael David | EVP, Pres, Medical | M - OptEx | $147.68 | +6,360 | 11.2K | +130% | +$939.2K |
| D | 2025-07-22 | 2025-07-18 | BDX | Garrison Michael David | EVP, Pres, Medical | D - Sale to Iss | $180.29 | -5,175 | 6,072 | -46% | -$933.0K |
| DM | 2025-07-22 | 2025-07-18 | BDX | Garrison Michael David | EVP, Pres, Medical | S - Sale+OE | $180.29 | -1,185 | 4,887 | -20% | -$213.6K |
| 2025-07-07 | 2025-07-02 | BDX | Muhsin Bilal | EVP, Pres Connected Care | A - Grant | $0.00 | +12.2K | 12.2K | New | $0 | |
| 2025-06-02 | 2025-06-02 | BDX | Shan David | EVP, Chief ISC Off | S - Sale | $171.19 | -1,166 | 4,575 | -20% | -$199.6K | |
| 2025-04-10 | 2025-04-09 | BDX | Garrison Michael David | EVP, Pres, Medical | S - Sale | $197.28 | -479 | 4,887 | -9% | -$94.5K | |
| 2025-04-07 | 2025-04-04 | BDX | Neal Shana Carol | EVP, CHRO | F - Tax | $0.00 | -1,886 | 13.5K | -12% | $0 | |
| 2025-03-27 | 2025-03-26 | BDX | HAYES GREGORY | Dir | A - Grant | $0.00 | +796 | 796 | New | $0 | |
| 2025-03-19 | 2025-03-18 | BDX | Byrd Richard | EVP, Pres Interventional | S - Sale | $230.00 | -459 | 6,952 | -6% | -$105.6K | |
| 2025-03-13 | 2025-03-12 | BDX | Byrd Richard | EVP, Pres Interventional | S - Sale | $224.91 | -1,940 | 7,411 | -21% | -$436.3K | |
| 2025-03-04 | 2025-03-01 | BDX | Garrison Michael David | EVP, Pres Medical | F - Tax | $0.00 | -178 | 5,366 | -3% | $0 | |
| 2025-02-12 | 2025-02-12 | BDX | SCOTT BERTRAM L | Dir | S - Sale | $227.99 | -700 | 36.0K | -2% | -$159.6K | |
| 2025-02-10 | 2025-02-10 | BDX | Henderson Jeffrey William | Dir | P - Purchase | $233.62 | +1,500 | 8,015 | +23% | +$350.4K | |
| 2025-01-30 | 2025-01-28 | BDX | RING TIMOTHY M | Dir | A - Grant | $0.00 | +930 | 57.9K | +2% | $0 | |
| 2025-01-30 | 2025-01-28 | BDX | Byington Carrie L | Dir | A - Grant | $0.00 | +930 | 3,834 | +32% | $0 | |
| 2025-01-30 | 2025-01-28 | BDX | Henderson Jeffrey William | Dir | A - Grant | $0.00 | +930 | 6,515 | +17% | $0 | |
| 2025-01-30 | 2025-01-28 | BDX | ECKERT R ANDREW | Dir | A - Grant | $0.00 | +930 | 9,170 | +11% | $0 | |
| 2025-01-30 | 2025-01-28 | BDX | BURZIK CATHERINE M | Dir | A - Grant | $0.00 | +930 | 14.3K | +7% | $0 | |
| 2025-01-30 | 2025-01-28 | BDX | Jones Christopher Ian Montague | Dir | A - Grant | $0.00 | +930 | 22.7K | +4% | $0 | |
| 2025-01-30 | 2025-01-28 | BDX | SCOTT BERTRAM L | Dir | A - Grant | $0.00 | +930 | 36.7K | +3% | $0 | |
| 2025-01-30 | 2025-01-28 | BDX | Fraser Claire | Dir | A - Grant | $0.00 | +930 | 24.0K | +4% | $0 | |
| 2025-01-30 | 2025-01-28 | BDX | Waldstreicher Joanne | Dir | A - Grant | $0.00 | +930 | 2,270 | +69% | $0 |
Purchase Sale Sale after option exercise All abbreviations